You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
12 Items
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab – In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
... Show more tags
Drugs Used:
bortezomib,
daratumumab,
dexamethasone
... Show more tags
Quick Link(s):
Regimen Monograph
Sep 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Exceptional Access Program
    lapatinib - Second-Line treatment of HER2 positive metastatic breast cancer in combination with chemotherapy after previous exposure to trastuzumab based treatments, with specific criteria
Exceptional Access Program
    lapatinib - Treatment of HER-2 positive metastatic breast cancer when used in combination with chemotherapy after use of trastuzumab in patients who have an adverse drug reaction or contraindication to trastuzumab therapy
... Show more tags
Drugs Used:
capecitabine,
lapatinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Drugs Used:
daratumumab (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab – In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
... Show more tags
Drugs Used:
daratumumab
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab – In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    lenalidomide - For the treatment of patients with multiple myeloma with good performance status who have received at least one prior therapy.
... Show more tags
Drugs Used:
daratumumab,
dexamethasone,
lenalidomide
... Show more tags
Quick Link(s):
Regimen Monograph
Jul 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
... Show more tags
Drugs Used:
daSATinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
... Show more tags
Drugs Used:
daSATinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Drugs Used:
lorlatinib (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Gastrointestinal, Colorectal     
Intent: Palliative
Drugs Used:
regorafenib (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Gastrointestinal, Gastrointestinal Stromal Tumours, Sarcoma, GIST     
Intent: Palliative
Funding:
Exceptional Access Program
    regorafenib - For the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST), according to specific criteria.
... Show more tags
Drugs Used:
regorafenib
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Gastrointestinal, Hepatobiliary / Liver / Bile Duct     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of hepatocellular carcinoma according to clinical criteria
... Show more tags
Drugs Used:
regorafenib
... Show more tags
Quick Link(s):
Regimen Monograph
Sep 2019
Cancer Type: Gastrointestinal, Colorectal     
Drugs Used:
trifluridine / tipiracil (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019